Evidence map›Paper›PMID 28863160›Full record

ArticlePloS one2017

High rates of loss to follow-up during the first year of pre-antiretroviral therapy for HIV patients at sites providing pre-ART care in Nigeria, 2004-2012.

Simon G Agolory, Andrew F Auld, Solomon Odafe, Ray W Shiraishi, E Kainne Dokubo, Mahesh Swaminathan, Ibrahim Dalhatu, Dennis Onotu, Oseni Abiri, Henry Debem and 2 more

Abstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Observational
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Simon G AgoloryDivision of Global HIV & TB, U.S. Centers for Disease Control & Prevention, Atlanta, United States of America.
Andrew F AuldDivision of Global HIV & TB, U.S. Centers for Disease Control & Prevention, Atlanta, United States of America.
Solomon OdafeDivision of Global HIV & TB, U.S. Centers for Disease Control & Prevention, Abuja, Nigeria.ORCID http://orcid.org/0000-0002-2452-0532
Ray W ShiraishiDivision of Global HIV & TB, U.S. Centers for Disease Control & Prevention, Atlanta, United States of America.
E Kainne DokuboDivision of Global HIV & TB, U.S. Centers for Disease Control & Prevention, Atlanta, United States of America.
Mahesh SwaminathanDivision of Global HIV & TB, U.S. Centers for Disease Control & Prevention, Atlanta, United States of America.
Ibrahim DalhatuDivision of Global HIV & TB, U.S. Centers for Disease Control & Prevention, Abuja, Nigeria.
Dennis OnotuDivision of Global HIV & TB, U.S. Centers for Disease Control & Prevention, Abuja, Nigeria.
Oseni AbiriDivision of Global HIV & TB, U.S. Centers for Disease Control & Prevention, Abuja, Nigeria.
Henry DebemDivision of Global HIV & TB, U.S. Centers for Disease Control & Prevention, Abuja, Nigeria.
Adebobola BashorunNational AIDS & STIs Control Program, Federal Ministry of Health, Abuja, Nigeria.
Tedd V EllerbrockDivision of Global HIV & TB, U.S. Centers for Disease Control & Prevention, Atlanta, United States of America.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWith about 3.4 million HIV-infected persons, Nigeria has the second highest number of people living with HIV (PLHIV) in the world. However, antiretroviral treatment (ART) coverage in Nigeria remains low with only 748,846 (22%) of PLHIV on ART by the end of 2014. Retention of HIV-infected patients in pre-ART care is essential to ensure timely ART initiation. We assessed outcomes of patients enrolled in Nigeria's pre-ART program during 2004-2012.

methodsWe conducted a nationally representative retrospective cohort study among adults (≥15 years old), enrolling in pre-ART programs supported by the U.S. President's Emergency Plan for AIDS Relief in Nigeria. A total of 35 sites enrolling ≥50 patients in pre-ART were selected using probability proportional-to-size sampling; 2,415 eligible medical records at these sites were randomly selected for abstraction. Determinants of loss to follow-up (LTFU) and mortality during pre-ART care were estimated using Cox proportional hazards regression models.

resultsThe median age at enrollment was 32 years (interquartile range (IQR) 27-40). A total of 1,216 (51.4%) initiated ART by the time of data abstraction. Among the remaining 1,199 patients, 898 (74.9%) had been LTFU, 180 (15.0%) were alive and in pre-ART care, 71 (5.9%) had died, 50 (4.2%) had transferred out or stopped care. Baseline markers of advanced disease, including weight <45 kg (adjusted hazard ration (AHR) = 4.23; 95% confidence interval (CI): 1.51-15.58) and more advanced WHO disease stage, were predictive of pre-ART mortality. Compared with patients aged 15-24, patients aged 35-44 (AHR = 0.67; 95% CI: 1.0.47-0.95) and age 45-54 (AHR = 0.66; 95% CI: 0.48-0.91) had lower LTFU rates. Compared with attending facilities in North Central geopolitical zone, attending facility locations in South East (AHR = 0.44; 95% CI: 0.24-0.83) was protective against LTFU.

conclusionsAbout half of patients enrolling in HIV program during 2004-2012 in Nigeria had not initiated ART by 2013. Key strategies to improve early ART initiation among pre-ART enrollees include implementation of the WHO test and treat guidelines, earlier HIV testing, and better monitoring to improve ART initiation rates. Further research to understand regional variations in pre-ART outcomes is warranted.

Indexed as

Lost to Follow-UpAdolescentAdultAnti-HIV AgentsAnti-Retroviral AgentsAntiretroviral Therapy, Highly ActiveCD4 Lymphocyte CountCommunicable Disease ControlFemaleFollow-Up StudiesHIV InfectionsHumansMaleMiddle AgedNigeriaProportional Hazards ModelsAnti-HIV AgentsAnti-Retroviral Agents

Identifiers

PMID28863160
PMCPMC5581182

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.